3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
4
Unknown
1
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neoplasms
3
Glioblastoma
3
Neuroblastoma
2
Lymphoma
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Malignant Solid Tumor
2
Thymoma
1
Retinoblastoma
1
Resectable Pancreatic Cancer
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Objective Response Rate
1
Neoplasm Metastasis
1
Myasthenia Gravis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Hepatoblastoma
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Advanced Refractory Solid Tumors
1
Interventions
Temozolomide
16
Radiotherapy
7
apatinib
5
anlotinib
3
Surgical Procedures, Operative
3
Chlorotoxin
3
Bevacizumab
3
Aminolevulinic Acid
3
Positron Emission Tomography Computed Tomography
2
Pemetrexed
2
Magnetic Resonance Spectroscopy
2
Lomustine
2
Irinotecan
2
Immunotherapy, Adoptive
2
Blood Specimen Collection
2
vandetanib
1
sodium thiosulfate
1
ribociclib
1
poly ICLC
1
lonafarnib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
etoposide phosphate
1
Vinblastine
1
Valproic Acid
1
Tranexamic Acid
1
Surveys and Questionnaires
1
Sunitinib
1
Rivaroxaban
1
Radiosurgery
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Glioma
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
Clear all
NCT03392545
2019-07-11
InSituVac1
Beijing Tiantan Hospital
Phase 1
Unknown
30 enrolled